Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

A cancer patient who had bad luck with clinical trials

Nathan A. Pennell, MD, PhD
Conditions
October 30, 2015
Share
Tweet
Share

asco-logo I am superstitious, and I freely admit it. I don’t use the word “cure” with patients until the 5-year scan has come and gone cleanly. I don’t celebrate the scans showing tumor response until I see them myself and make sure I am not mixing up the new scan with the old. And one of my most closely held superstitions is that the nicest patients seem to have the worst luck. We used to note morbidly in fellowship that sweet dispositions were a poor prognostic sign, as if our patients’ bad outcomes were punishments to us for coming to care about them. Nonsense of course, and yet absolutely true. Wait, what’s recall bias?

I was reading the recent post by ASCO President Julie Vose titled “Why is getting a patient on a clinical trial so difficult?” Dr. Vose’s post made me think of a patient of mine who seemed to have the just opposite problem: She could get onto any trial I suggested, but couldn’t seem to buy a break.

Mrs. K is a wonderful 65-year-old woman who just makes you smile when you see her. She is sunny and optimistic, with a quiet and supportive spouse who complements her well. She came to me in 2013 with metastatic non-small cell lung cancer, and together we decided to enroll her on a clinical trial we had open at the time. She agreed in the spirit that it might help someone else even if she didn’t get any benefit. She was randomly assigned to chemotherapy plus drug or placebo; we never knew which, and initially it worked but before long her cancer was advancing again. That trial was eventually reported to be completely negative for any benefit from the experimental drug.

We had a second-line trial open as well, and again we discussed the options and she decided to enroll. This one was randomized but not blinded, and she was assigned to chemotherapy alone. She took this disappointment in stride, but, unfortunately, her cancer took it in stride as well and progressed despite the chemotherapy.

Still, she felt good and wanted to do something more, so I offered her a third clinical trial. This one was a harder sell, because it required a new biopsy, and she could only go on the trial if a potential biomarker was positive on the biopsy. We discussed the pros and cons, and I informed her that the results with this drug had been quite good in the biomarker-positive tumors, and anyway the odds were about 50-50 so maybe she would get lucky this time. She smiled, agreed, and you can guess the rest. The biopsy was negative, and she was not eligible for the trial.

It was hard to escape the feeling that luck simply wasn’t with her, but we had just gotten an open slot on a trial of a similar drug that did not require a biomarker test. She was having chest pain at that point and losing some weight, but it hadn’t dulled her smile in the least. “Whatever you suggest, Doctor. I trust you.” I could feel an almost palpable sense of doom.

We started her on the trial, and her first set of restaging scans looked worse, which I had come to expect by this time. However, when I saw her to discuss them, her symptoms had actually started to improve. Her pain was almost gone, which didn’t make much sense, but this new drug belongs to a class of drugs that can have delayed responses, so we decided to continue it anyway. I also didn’t have a better suggestion to try.

When I saw her next, she looked fantastic, with no pain and back to her baseline weight. I remember she even complimented me on my Van Gogh tie. When I opened her scans, I double-checked to make sure I had them in the right order, but there was no mistaking what I saw. Or rather didn’t see. She had had a complete response, to which I can only attribute a secretive, nasty streak that she hides from all of us in clinic. I am on to you, Mrs. K. Your delicious Christmas cookies can’t fool me!

On a recent visit over a year later, feeling well and still without any sign of cancer, she told me she knew all along we would find something that would work. She had faith that things would come out OK, and gently chided me for continuing to hedge about the future. I am happy to admit I was wrong, that my superstition about her bad luck was completely ridiculous, and that I have learned a valuable lesson. And if I just happened to be wearing Starry Night on my tie again, I’m sure it was just a coincidence.

Nathan A. Pennell is an oncologist who blogs at ASCO Connection, where this post originally appeared.

Image credit: Shutterstock.com

Prev

The unsettling incongruity of a medical student's "lucky" day

October 30, 2015 Kevin 1
…
Next

An episode of low-value care delivered to my father

October 30, 2015 Kevin 25
…

Tagged as: Oncology/Hematology

Post navigation

< Previous Post
The unsettling incongruity of a medical student's "lucky" day
Next Post >
An episode of low-value care delivered to my father

ADVERTISEMENT

More by Nathan A. Pennell, MD, PhD

  • How social media changed this oncologist’s life

    Nathan A. Pennell, MD, PhD
  • An oncologist reflects on his inpatient internal medicine service

    Nathan A. Pennell, MD, PhD
  • This is why a computer algorithm cannot ever fully replace a doctor’s judgment

    Nathan A. Pennell, MD, PhD

Related Posts

  • A letter to a cancer patient in palliative care

    Alison Vasa
  • Happy National Grateful Patient Day!

    R. Lynn Barnett
  • My first patient to be diagnosed with cancer

    Ton La, Jr., MD, JD
  • A silent moment with a dying patient

    Ramses Perez
  • Including the patient perspective on tumor boards

    Don S. Dizon, MD
  • Losing my first patient

    Allie Poles

More in Conditions

  • Addressing menstrual health inequities in adolescents

    Callia Georgoulis
  • Healing beyond the surface: Why proper chronic wound care matters

    Alvin May, MD
  • Why specialist pain clinics and addiction treatment services require strong primary care

    Olumuyiwa Bamgbade, MD
  • What a childhood stroke taught me about the future of neurosurgery and the promise of vagus nerve stimulation

    William J. Bannon IV
  • Facing terminal cancer as a doctor and mother

    Kelly Curtin-Hallinan, DO
  • Why doctors must stop ignoring unintentional weight loss in patients with obesity

    Samantha Malley, FNP-C
  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • America’s ER crisis: Why the system is collapsing from within

      Kristen Cline, BSN, RN | Conditions
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
    • FDA delays could end vital treatment for rare disease patients

      GJ van Londen, MD | Meds
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
  • Recent Posts

    • Why clinical research is a powerful path for unmatched IMGs

      Dr. Khutaija Noor | Education
    • Addressing menstrual health inequities in adolescents

      Callia Georgoulis | Conditions
    • How to advance workforce development through research mentorship and evidence-based management

      Olumuyiwa Bamgbade, MD | Physician
    • The truth about perfection and identity in health care

      Ryan Nadelson, MD | Physician
    • Civil discourse as a leadership competency: the case for curiosity in medicine

      All Levels Leadership | Physician
    • Healing beyond the surface: Why proper chronic wound care matters

      Alvin May, MD | Conditions

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 4 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • America’s ER crisis: Why the system is collapsing from within

      Kristen Cline, BSN, RN | Conditions
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
    • FDA delays could end vital treatment for rare disease patients

      GJ van Londen, MD | Meds
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
  • Recent Posts

    • Why clinical research is a powerful path for unmatched IMGs

      Dr. Khutaija Noor | Education
    • Addressing menstrual health inequities in adolescents

      Callia Georgoulis | Conditions
    • How to advance workforce development through research mentorship and evidence-based management

      Olumuyiwa Bamgbade, MD | Physician
    • The truth about perfection and identity in health care

      Ryan Nadelson, MD | Physician
    • Civil discourse as a leadership competency: the case for curiosity in medicine

      All Levels Leadership | Physician
    • Healing beyond the surface: Why proper chronic wound care matters

      Alvin May, MD | Conditions

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

A cancer patient who had bad luck with clinical trials
4 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...